4D Molecular Therapeutics, Inc. (FDMT)
| Market Cap | 224.23M |
| Revenue (ttm) | 13.61M |
| Net Income (ttm) | -56.69M |
| Shares Out | 6.43M |
| EPS (ttm) | -8.82 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 22 |
| Last Price | $34.87 |
| Previous Close | $33.25 |
| Change ($) | 1.62 |
| Change (%) | 4.87% |
| Day's Open | 33.56 |
| Day's Range | 33.10 - 36.28 |
| Day's Volume | 100,831 |
| 52-Week Range | 30.55 - 55.11 |
- First patient dosed in the 4D-310 Phase 1/2 clinical trial in Fabry disease
EMERYVILLE, Calif., March 09, 2021 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: 4DMT), a clinical-stage gene therapy company harnessing the power of directed evolution for targeted gene therap...
Andreas Halvorsen (Trades, Portfolio) has revealed two new buys in 4D Molecular Therapeutics Inc. (NASDAQ:FDMT) and AbCellera Biologics Inc. (NASDAQ:ABCL), according to GuruFocus' Real-Time Picks, a Pre...
EMERYVILLE, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...
EMERYVILLE, Calif., Dec. 10, 2020 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics, Inc. (4DMT), a clinical-stage gene therapy company harnessing the power...
4D Molecular Therapeutics, a Phase 1/2 gene therapy biotech developing novel AAVs for ophthalmic diseases, raised the proposed deal size for its upcoming IPO on Thursday. The Emeryville, CA-based compan...
4D Molecular Therapeutics, which is developing targeted gene therapies for multiple diseases, filed on Tuesday with the SEC to raise up to $75 million in an initial public offering.
4D Molecular Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.
About FDMT
4D Molecular Therapeutics is a clinical-stage gene therapy company pioneering the development of product candidates using our targeted and evolved AAV vectors. We seek to unlock the full potential of gene therapy using our platform, Therapeutic Vector Evolution, which combines the power of directed evolution with our approximately one billion synthetic capsid sequences to invent evolved vectors for use in targeted gene therapy products. Our targeted and evolved vectors are invented with the goal of being delivered through clinically routine, we... [Read more...]
| Industry Biotechnology | IPO Date Dec 11, 2020 |
| CEO David Kirn | Employees 83 |
| Stock Exchange NASDAQ | Ticker Symbol FDMT |
Financial Performance
In 2020, FDMT's revenue was $13.61 million, an increase of 94.85% compared to the previous year's $6.99 million. Losses were -$56.69 million, 15.0% more than in 2019.
Analyst Forecasts
The average 12-month stock price forecast for FDMT is 56.00, which is an increase of 60.60% from the latest price.